Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF) (2019 - 2026)

Mirum Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 13.58% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $25.1 million, a 4.37% increase from a year earlier, with the FY2025 full-year figure at $24.2 million, up 2.6% from the prior year.
• Depreciation & Amortization (CF) rose to $6.9 million in Q1 2026 per MIRM's latest filing, from $6.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $6.9 million in Q1 2026 and bottomed at $342000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $5.7 million (2024), against an average of $4.0 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 1204.76% in 2022 and increased 0.12% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.2 million in 2022, then soared by 357.45% to $5.5 million in 2023, then climbed by 10.23% to $6.1 million in 2024, then gained by 0.3% to $6.1 million in 2025, then gained by 13.17% to $6.9 million in 2026.
• Per Business Quant, the three latest MIRM Depreciation & Amortization (CF) figures stand at $6.9 million (Q1 2026), $6.1 million (Q4 2025), and $6.1 million (Q3 2025).